A Comparative Analysis of the REDAPT System in Revision Total Hip Arthroplasty: Evidence From a Large US Claims Database
Author(s)
Boxuan Li, MSc1, Leo M. Nherera, BSc, MSc, PhD2.
1Global Market Access- HEOR Data Analytics, Smith + Nephew, Fort Worth, TX, USA, 2Director Health Economics, Smith & Nephew Inc, Colleyville, TX, USA.
1Global Market Access- HEOR Data Analytics, Smith + Nephew, Fort Worth, TX, USA, 2Director Health Economics, Smith & Nephew Inc, Colleyville, TX, USA.
OBJECTIVES: Healthcare costs associated with hip revisions remain underexplored compared to those of primary hip replacements. The REDAPT™* revision system with oxidized zirconium (OxZr), hereafter referred to as REDAPT, aims to enhance clinical and economic outcomes in hip revision procedures. This study aimed to compare the short-term resource utilization of REDAPT with non-REDAPT systems in revision hip procedures.
METHODS: A retrospective analysis of hip revisions (November 2016-March 2024) was conducted using the Premier PINC AI Healthcare database, covering approximately 25% of U.S. annual inpatient admissions. Patients with six-month baseline data and 12-month follow-up data were included; those under 21 years of age or with missing demographic or cost data were excluded. REDAPT cases were identified using ICD-10-PCS codes and billing keywords. A 1:3 propensity score matching ensured comparability of cohort baseline characteristics, followed by generalized regression models to assess differences in outcomes between interventions.
RESULTS: The study matched 1,146 REDAPT patients with 3,425 non-REDAPT patients, achieving balanced baseline characteristics. REDAPT patients had significantly lower odds of all-cause readmission within a year (OR 0.81, CI 0.71-0.92, p=0.002), dislocation (OR 0.71, CI 0.57-0.88, p=0.002), periprosthetic/wound infections (OR 0.71, CI 0.56-0.9, p=0.006), infection/inflammatory reactions (OR 0.62, CI 0.53-0.72, p<0.001), and sepsis/septicemia/shock within 180 days (OR 0.62, CI 0.46-0.82, p=0.001). REDAPT patients also had a shorter length of stay (4.24 vs. 4.96 days, p = 0.032) and fewer readmissions within 180 days (1.21 vs. 1.42, p = 0.001) compared to non-REDAPT treated patients.
CONCLUSIONS: The REDAPT system with OxZr demonstrates superior clinical and resource utilization outcomes in hip revision procedures compared to non-REDAPT systems. The adoption of effective medical devices, such as REDAPT, can improve patient outcomes while optimizing healthcare expenditures.
*Trademark of Smith+Nephew. All Trademarks acknowledged. (Smith + Nephew, Inc. Memphis TN)
METHODS: A retrospective analysis of hip revisions (November 2016-March 2024) was conducted using the Premier PINC AI Healthcare database, covering approximately 25% of U.S. annual inpatient admissions. Patients with six-month baseline data and 12-month follow-up data were included; those under 21 years of age or with missing demographic or cost data were excluded. REDAPT cases were identified using ICD-10-PCS codes and billing keywords. A 1:3 propensity score matching ensured comparability of cohort baseline characteristics, followed by generalized regression models to assess differences in outcomes between interventions.
RESULTS: The study matched 1,146 REDAPT patients with 3,425 non-REDAPT patients, achieving balanced baseline characteristics. REDAPT patients had significantly lower odds of all-cause readmission within a year (OR 0.81, CI 0.71-0.92, p=0.002), dislocation (OR 0.71, CI 0.57-0.88, p=0.002), periprosthetic/wound infections (OR 0.71, CI 0.56-0.9, p=0.006), infection/inflammatory reactions (OR 0.62, CI 0.53-0.72, p<0.001), and sepsis/septicemia/shock within 180 days (OR 0.62, CI 0.46-0.82, p=0.001). REDAPT patients also had a shorter length of stay (4.24 vs. 4.96 days, p = 0.032) and fewer readmissions within 180 days (1.21 vs. 1.42, p = 0.001) compared to non-REDAPT treated patients.
CONCLUSIONS: The REDAPT system with OxZr demonstrates superior clinical and resource utilization outcomes in hip revision procedures compared to non-REDAPT systems. The adoption of effective medical devices, such as REDAPT, can improve patient outcomes while optimizing healthcare expenditures.
*Trademark of Smith+Nephew. All Trademarks acknowledged. (Smith + Nephew, Inc. Memphis TN)
Conference/Value in Health Info
2025-09, ISPOR Real-World Evidence Summit 2025, Tokyo, Japan
Value in Health Regional, Volume 49S (September 2025)
Code
RWD260
Topic Subcategory
Health & Insurance Records Systems
Disease
SDC: Musculoskeletal Disorders (Arthritis, Bone Disorders, Osteoporosis, Other Musculoskeletal)